Cantor Fitzgerald reiterated coverage on Amicus Therapeutics with a new price target
$FOLD
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald reiterated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $15.00 from $16.00 previously